relation from obesity to DM, but not vice versa, 14 even if the patients with DM lose less weight than similarly obese patients without DM. 15 Furthermore, systematic reviews of high-quality and consistent evidence show that the use of body mass index (BMI) to define obesity is highly specific, but has low to moderate sensitivity. 16, 17 Although it is a simple, convenient, and noninvasive surrogate measure of body fat, it is a measure of excess weight per height rather than a direct measure of fat mass. 18 Therefore, there is no demonstration of an "obesity paradox" based on a direct measurement of body fat contrast to use of BMI as an index of obesity. 18, 19 The waist to hip circumference ratio (normally <0.95 for men and <0.85 for women) is generally a better prognostic indicator for disease than the BMI, 20 especially when the BMI is <35. 21 A genetic predisposition to abdominal adiposity evaluated by higher waist to hip ratio adjusted for BMI was associated with increased risk of type 2 DM and CAD. 22, 23 Elagizi et al discussed the utility and limitations of BMI for cardiometabolic risk stratification, 24 and Gregory et al reported no association of BMI with 1-year allcause or cardiac-specific mortality after adjustment for potential confounding variables such as DM. 25 Although Asians with DM and ACS are less likely to be obese than their white counterparts, their risk of death or recurrent ischemic events was not lower. 26 Although obesity is often considered a relatively "minor" CAD risk factor, weight loss is a broadly effective intervention by influencing a number of "major" risk factors, especially DM and hypertension. 27 All of this needs to be taken into consideration when interpreting diabesity trials. 18 A study outcome can be statistically significant, but not clinically significant and vice versa. 28 Diabesity and DM are often used interchangeably and there is a need to decide which factors are confounders before applying any statistical correction method. One of the fundamental assumptions underlying analysis of covariance (ANCOVA) is that of no interaction between factor and covariate. Due to mostly one-directional relation from obesity to DM but not vice versa, 14 the ANCOVA analysis was not considered suitable for adjustment for obesity due to the diabesity interaction. However, in the light of the author's request, we analyzed, by ANCOVA tests, the influence of the BMI on Gensini and SYNTAX scores and whether HbA 1c -based classification effects were retained regardless of "body weight" influence. The results remained significant after adjusting for BMI for both SYNTAX (F ¼ 7.72, P < .01) and Gensini scores (F ¼ 6.95, P < .01). Since we included patients with previous DM on antidiabetic or insulin therapy into the DM group, it would not be appropriate to compare HbA 1c levels between the DM and prediabetic groups.
Type 2 DM will remain one of the greatest challenges to human health for many years to come, and the primordial prevention of the obesity tsunami would be a major strategy for reducing the DM avalanche. 29 Therefore, it is urgent to take steps including screening, prevention, and early management in an attempt to control this evolving epidemic of diabesity. [30] [31] [32] [33] The most recent guidelines by the European Society of Cardiology in collaboration with European Association for the Study of DM recommend that all patients with ACS should be screened for DM. 34 Looking to the future, it has been suggested that the "thrombocardiologist" of the 20th century is being replaced by the "diabeto-cardiologist" of the 21st century. 35 Because the cardiologist often may be the first clinician to diagnose patients with ACS with DM or prediabetes, 36 it is incumbent upon them to understand the disease process and the interventions necessary to improve outcome. 37 
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